Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SHANGHAI HENLIUS BIOTECH, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 12.26 HKD | -3.77% | -8.64% | -4.22% | |
| Nov. 29 | Henlius Biotech's Unit Passes Colombian Drug Regulator's Inspection | MT |
| Nov. 27 | US Regulator Green Lights Henlius Biotech’s Phase 1 Trial for Anti-Tumor Drug | MT |
| Sales 2023 * | 5.04B 701M 5.47B | Sales 2024 * | 5.5B 765M 5.97B | Capitalization | 6.35B 884M 6.9B |
|---|---|---|---|---|---|
| Net income 2023 * | 463M 64.43M 503M | Net income 2024 * | 568M 79.04M 617M | EV / Sales 2023 * | 1,26x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 1,16x |
| P/E ratio 2023 * | 13,6x | P/E ratio 2024 * | 11,1x | Employees | 3,406 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 21.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.77% | ||
| 1 week | -8.64% | ||
| Current month | -9.19% | ||
| 1 month | -7.40% | ||
| 3 months | +2.17% | ||
| 6 months | +11.45% | ||
| Current year | -4.22% |
1 week
12.08
13.48
1 month
12.0815.36
Current year
9.6017.40
1 year
9.6017.40
3 years
9.6048.10
5 years
9.6067.05
10 years
9.6067.05
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Zhu
CEO | Chief Executive Officer | 45 | 2021 |
Wei Dong Jiang
FOU | Founder | - | 2009 |
Wen Jie Zhang
CHM | Chairman | 56 | 2019 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 51 | 2013 |
Tak Young So
BRD | Director/Board Member | 53 | 2019 |
Xiao Hui Guan
BRD | Director/Board Member | 52 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.13% | 55 M€ | -26.81% | - | |
| 0.04% | 2 M€ | 0.00% | ||
| 0.02% | 56 M€ | +10.06% | - | |
| 0.01% | 723 M€ | +13.71% | - | |
| 0.01% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-11 | 12.26 | -3.77% | 59 371 |
| 23-12-08 | 12.74 | +2.91% | 113,100 |
| 23-12-07 | 12.38 | -3.28% | 162,100 |
| 23-12-06 | 12.8 | -1.84% | 124,900 |
| 23-12-05 | 13.04 | -2.83% | 216,700 |
Delayed Quote Hong Kong Stock Exchange, December 11, 2023 at 12:11 am EST
More quotes
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Sector
Pharmaceuticals
Calendar
2024-03-26
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
11.69CNY
Average target price
14.18CNY
Spread / Average Target
+21.38%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.22% | 887 M $ | |
| -6.93% | 84 806 M $ | |
| -13.64% | 38 355 M $ | |
| -13.59% | 34 673 M $ | |
| +6.30% | 20 852 M $ | |
| -10.19% | 17 507 M $ | |
| -52.55% | 15 921 M $ | |
| +4.13% | 15 625 M $ | |
| -31.90% | 12 259 M $ | |
| +31.71% | 9 109 M $ |
